Atherosclerosis

Hot off the press 🔥 The #EAS2025 abstracts have just been published in Atherosclerosis! Check out the cutting-edge research shaping the future of lipid & cardiovascular science 👉 atherosclerosis-journal.com/issue/S0021-91… 🌟 #EASSoMe @society_eas

The exposome offers a vital lens for future research, policy, and preventive cardiovascular medicine, helping to address the health burden posed by our changing environment 🔗 atherosclerosis-journal.com/article/S0021-… @society_eas #EASSoMe

What are the chances of 2 Balance FCS papers coming out in the same day? Answer= 100% 😀 This one done @UCSDCardiology shows a novel technique to measure apoC-III in different lipoprotein pools and selective effect of olezarsen on total apoB (apoB-48+apoB-100) and apoA-I pools…

New editorial in @ATHjournal highlights our latest work! Using an AI-driven method to extract aortic diameters from EHRs, we uncover sex-specific responses to antiplatelet therapy. Read more: atherosclerosis-journal.com/article/S0021-…

Published in Atherosclerosis; Our joint editorial by @society_eas EC & the @ATHjournal editorial board — reaffirming the critical need for #sex & #gender integration in ASCVD research & clinical care. 🧬 Sex hormones, chromosomes & social roles all matter. ⚠️ Without this lens,…

Plaques with spotty calcification, compared with those with advanced calcification, have a higher level of vascular inflammation 🔗atherosclerosis-journal.com/article/S0021-… @society_eas #EASSoMe

🔬 Targeting ANGPTLs: A New Frontier in Lipid Management? ANGPTLs are emerging as key regulators of lipid metabolism — and promising targets in the fight against ASCVD 🔗atherosclerosis-journal.com/article/S0021-… @society_eas @ELS_Cardiology #EASSoMe #CvPrev

Multiomics in atherosclerotic cardiovascular disease - Atherosclerosis atherosclerosis-journal.com/article/S0021-… The future is now. Beautifull review from AtheroNet group. Proud of taking part of this action!

This new review in @ATHjournal sounds promising! Understanding the link between adipose tissue dysfunction and atherosclerosis is crucial, especially for patients with lupus who are at heightened cardiovascular risk.

🚨 Coming soon in @ATHjournal ! A powerful new review explores the link between adipose tissue dysfunction and atherosclerosis, shedding light on innovative therapies. This comprehensive review explores the complex interplay between adipose tissue dysfunction and…

Lipoprotein(a) Reduction with Lipid-Lowering Drugs – What Works in 2025? 🧾 Atherosclerosis, June 2025 | Meta-analysis of 147 RCTs, 145,314 patients 👨‍⚕️ Study by Xie S, Galimberti F, Catapano AL et al. @Lipidaoi1 @nationallipid @TrackYourHeart @googledocs @MEDICALGUR39690…

New meta-analysis on lipid-lowering drugs & #Lp(a) shows: • PCSK9 mAbs, inclisiran, CETP-i & niacin ↓ Lp(a) • Greater absolute drop when baseline Lp(a) is very high Still no therapy dedicated to Lp(a) – big gap for #CVrisk research atherosclerosis-journal.com/article/S0021-…

SEX AND GENDER IN ATHEROSCLEROSIS ⚧️It's essential rol in CV researc ⚧️A statement from the Editorial Board of Atherosclerosis and Executive Committee of the European Atherosclerosis Society ⚧️Highlights on . Sex differences . Transgender individuals . Gender differences #CardioX

By focusing on both AAA and TAA, as well as sex-specific effects, these findings shed 💡 on the complexity of aneurysm management. This study underscores the need for further research to develop tailored therapeutic strategies 🔗atherosclerosis-journal.com/article/S0021-… @society_eas @MoradiShayan

☝️Effect of Lipid-lowering Therapies on Lp(a) Levels: A Comprehensive Meta-analysis of RCTs ☝️New evidence just published in @ATHjournal ! 👉This comprehensive meta-analysis of 147 RCTs involving over 145,000 participants confirms that most currently available lipid-lowering…

Think different, think #VLDL in #NAFLD #Atherosclerosis

Spotty calcification might be useful to identify patients at higher risk for future cardiac events 🔗atherosclerosis-journal.com/article/S0021-… @society_eas #EASSoMe

Targeting ANGPTLs could represent a promising strategy to reduce residual cardiovascular risk and complement existing lipid-lowering therapies 🔗atherosclerosis-journal.com/article/S0021-… @society_eas @ELS_Cardiology #EASSoMe #CvPrev

Although underlying risk factors including CKD, DM, excess visceral adiposity, and dyslipidemia are each independently associated w/ ASCVD, important mechanistic and clinical synergies exist between these conditions 🔗atherosclerosis-journal.com/article/S0021-… @society_eas @ELS_Cardiology #CvPrev

Racial differences in #aortic perivascular adipose tissue volume and its association with arterial stiffness #Atherosclerosis atherosclerosis-journal.com/article/S0021-…